Interferon Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Type I interferons (IFN-I), originally characterized as antiviral cytokines, have emerged as potent drivers of [neuroinflammation[/mechanisms/neuroinflammation and neurodegeneration across multiple diseases including [Alzheimer's disease[/diseases/alzheimers, [Parkinson's disease[/diseases/parkinsons, [ALS[/diseases/als, and [Huntington's disease[/mechanisms/huntington-pathway. The [cGAS-[STING[/entities/sting-pathway pathway], a cytosolic DNA sensing system, serves as a major upstream activator of IFN-I production in the aging and diseased brain. [microglia[/cell-types/microglia, IFN-β, IFN-ε, IFN-κ, and IFN-ω. All signal through a common heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits. Receptor engagement activates the JAK-STAT signaling cascade:
- Receptor binding: IFN-I binds IFNAR1/IFNAR2
- JAK activation: Tyrosine kinases JAK1 and TYK2 are phosphorylated
- STAT signaling: STAT1 and STAT2 are phosphorylated, form heterodimers, and associate with IRF9 to form the ISGF3 complex
- Gene induction: ISGF3 translocates to the nucleus and activates hundreds of interferon-stimulated genes (ISGs) by binding to ISRE promoter elements
ISGs encode proteins involved in antiviral defense, immune modulation, cell death, and inflammation. In the context of neurodegeneration, chronic ISG activation contributes to sustained inflammation, complement-mediated synapse loss, and neuronal death (Bhatt & Taylor, 2022) [2].
In the healthy brain, IFN-I signaling is maintained at low basal levels and plays homeostatic roles:
- Regulation of [microglial/Blood-Brain Barrier (BBB) integrity
- Defense against neurotropic viral infections
Dysregulated or chronic IFN-I activation, however, shifts [microglia/cGAS-STING pathway] is the principal driver of IFN-I production in neurodegeneration. The signaling cascade proceeds as follows:
- DNA sensing: Cyclic GMP-AMP synthase (cGAS) detects double-stranded DNA (dsDNA) in the cytosol — an abnormal location that signals cellular damage or pathogen invasion
- Second messenger synthesis: Activated cGAS catalyzes synthesis of 2'3'-cyclic GMP-AMP (cGAMP), a second messenger
- [STING[/entities/sting-pathway activation: cGAMP binds [STING[/entities/sting-pathway (Stimulator of Interferon Genes) on the [endoplasmic reticulum] membrane, triggering [STING[/entities/sting-pathway dimerization and translocation to the Golgi
- TBK1/IRF3 signaling: [STING[/entities/sting-pathway recruits TBK1, which phosphorylates IRF3, driving nuclear translocation and IFN-β transcription
- [NF-κB[/entities/nf-kb co-activation: [STING[/entities/sting-pathway also activates [NF-κB[/entities/nf-kb, amplifying pro-inflammatory cytokine production including IL-6, TNF-α, and IL-1β
Multiple pathological processes generate the cytosolic dsDNA that activates cGAS-[STING[/entities/sting-pathway:
- [Mitochondrial dysfunction[/mechanisms/mitochondrial-dysfunction: Damaged mitochondria release mtDNA into the cytosol through permeabilized membranes. This is particularly relevant in [Parkinson's disease[/diseases/parkinsons, where mitochondrial damage in [dopaminergic [neurons[/entities/neurons/cell-types/dopaminergic-[neurons) is a hallmark
- [DNA damage]: Accumulation of unrepaired nuclear DNA damage leads to micronuclei formation and cytosolic DNA leakage. Age-related decline in DNA repair capacity exacerbates this process
- Nuclear envelope breakdown: Compromised nuclear envelope integrity, observed in [ALS[/diseases/als and [FTD[/diseases/ftd associated with [nucleocytoplasmic transport defects[/mechanisms/nucleocytoplasmic-transport-defects, allows nuclear DNA to access the cytoplasm
- Retroelement activation: [Epigenetic] changes during aging and disease de-repress endogenous retroelements, producing cytosolic DNA intermediates
- Failed autophagy: Impaired clearance of damaged organelles by [autophagy[/entities/autophagy allows persistent accumulation of cytosolic DNA
These diverse sources converge on cGAS-STING activation, making IFN-I signaling a common downstream effector of multiple neurodegenerative pathologies (Gulen et al., 2023) [3].
Single-cell and single-nucleus RNA sequencing studies have revealed that IFN-I signaling drives [microglia/cell-types/microglia into a transcriptionally distinct state termed interferon-response [microglia[/entities/microglia (IRM), characterized by high expression of ISGs including Ifit3, Ifitm3, Isg15, Mx1, Stat1, and Oas1 (Lopez-Atalaya & Bhatt, 2025) [4].
IRM are distinct from other microglial activation states:
| Microglial State |
Key Markers |
Primary Function |
Disease Relevance |
| Homeostatic |
Tmem119, P2ry12, Cx3cr1 |
Surveillance |
Normal brain |
| [DAM (Disease-Associated) |
Trem2, Lgals3, Lpl, Cst7 |
Phagocytosis of debris |
AD, aging |
| IRM (IFN-Response) |
Ifitm3, Isg15, Mx1, Stat1 |
IFN-mediated inflammation |
AD, aging, viral |
| [Metabolically reprogrammed] |
Hif1a, Ldha, Pkm |
Glycolytic shift |
Chronic inflammation |
IRM represent a unique molecular state — they are not simply a subset of [DAM] or activated response [microglia[/cell-types/microglia, but a parallel activation program driven by a distinct signaling axis (Lopez-Atalaya & Bhatt, 2025) [5].
IRM exhibit pathological behaviors including:
- Excessive synaptic elimination: IRM upregulate [complement] proteins (C1q, C3, C4) and phagocytic receptors, mediating exaggerated [complement-mediated synapse loss[/mechanisms/complement-mediated-synapse-loss. IFN-I-activated [microglia engulf synapses at elevated rates, contributing to cognitive decline
- Pro-inflammatory cytokine release: IRM secrete neurotoxic mediators including IL-1β, IL-6, TNF-α, and [reactive oxygen species (ROS)[/entities/ros, creating a toxic microenvironment
- Reduced trophic support: IFN-I activation suppresses microglial production of [neurotrophic factors[/mechanisms/neurotrophic-factors such as [BDNF[/entities/bdnf and IGF-1
- Pyroptosis induction: IFN-I can prime the [NLRP3[/mechanisms/nlrp3-inflammasome inflammasome], leading to gasdermin D-mediated [pyroptosis[/mechanisms/pyroptosis in microglia, which releases inflammatory contents into the parenchyma
IFN-I signaling plays a multifaceted role in [Alzheimer's disease[/diseases/alzheimers:
- [Amyloid-Beta ([Aβ)-induced IFN-I: [Aβ[/entities/amyloid-beta oligomers and fibrils activate cGAS-STING in microglia through mechanisms involving mitochondrial stress and DNA damage. [Aβ[/entities/amyloid-beta accumulation stimulates cGAS-STING signaling, resulting in increased expression of interferon-induced transmembrane protein 3 (IFITM3), which promotes γ-secretase activity and further [Aβ[/entities/amyloid-beta production — creating a vicious feed-forward cycle (Roy et al., 2020)
- [Tau[/entities/tau-protein-driven IFN-I: Human tau] isoforms 410 and 441 exhibit intrinsic potential to stimulate the cGAS-STING signaling cascade in microglial cells, suggesting this mechanism underlies multiple [tauopathies[/mechanisms/tauopathies. Tau-induced IFN-I drives complement deposition and synapse loss
- Concerted signaling: Concerted IFN-I signaling between microglia and [neurons[/entities/neurons promotes memory impairment associated with amyloid plaques. Neuronal IFNAR1 signaling contributes directly to synaptic dysfunction and [cognitive] decline (Bhatt et al., 2022)
- Therapeutic evidence: Genetic or pharmacologic blockade of IFNAR1, cGAS, or STING reduces microglial activation, synapse loss, and cognitive deficits in AD mouse models
In [Parkinson's disease[/diseases/parkinsons, IFN-I signaling is intimately connected to mitochondrial dysfunction:
- STING activation induces [neuroinflammation[/mechanisms/neuroinflammation and degeneration of [dopaminergic neurons[/cell-types/dopaminergic-neurons via activation of downstream type I interferon and IRF7 signaling
- Mutations in [PINK1[/genes/pink1 and [Parkin[/genes/prkn — key [mitophagy[/mechanisms/mitophagy regulators — lead to accumulation of damaged mitochondria that leak mtDNA into the cytosol, chronically activating cGAS-STING
- [LRRK2[/genes/lrrk2 mutations, the most common genetic cause of PD, enhance IFN-I signaling in microglia
- [α-synuclein[/proteins/alpha-synuclein aggregates activate microglia through toll-like receptors and can also trigger cGAS-STING through mechanisms involving mitochondrial damage
¶ ALS and FTD
IFN-I activation is observed in [ALS[/diseases/als and [FTD[/diseases/ftd:
- [TDP-43[/proteins/tdp-43 pathology disrupts nucleocytoplasmic transport, allowing nuclear DNA to access the cytoplasm and activate cGAS-STING
- [C9orf72[/genes/c9orf72 repeat expansions, the most common genetic cause of ALS/FTD, produce dipeptide repeat proteins that impair nuclear pore function and activate innate immune signaling
- [FUS/proteins/fus mutations disrupt DNA damage repair, increasing genomic instability and cytosolic DNA accumulation
[Huntington's disease[/mechanisms/huntington-pathway exhibits cGAS-STING pathway activation driven by:
- Mitochondrial malfunction releasing mtDNA
- Impaired [autophagy[/entities/autophagy failing to clear cytosolic DNA
- Mutant [huntingtin[/proteins/huntingtin-mediated disruption of DNA repair mechanisms
Normal brain aging is characterized by progressive IFN-I activation. Fate-mapping studies demonstrate pervasive IFN-I activity during mouse brain aging, with microglial IFN-I signaling perpetuating [neuroinflammation[/mechanisms/neuroinflammation, neuronal dysfunction, and molecular aggregation. Age-related activation of endogenous retroelements and declining [DNA repair] capacity contribute to chronic cGAS-STING activation (Minter et al., 2024) [6].
Monogenic type I interferonopathies — genetic disorders characterized by constitutive IFN-I activation — provide powerful evidence for the neurotoxicity of chronic IFN-I signaling:
- Aicardi-Goutières syndrome: Caused by mutations in nucleic acid metabolism genes (TREX1, RNASEH2A/B/C, SAMHD1, ADAR1, IFIH1), featuring progressive white matter disease and neurodegeneration
- RNaseT2-deficient leukoencephalopathy: Features severe psychomotor retardation driven by chronic IFN-I activation. Mouse models show microglial pyroptosis driven by type I interferon signaling
- STING-associated vasculopathy with onset in infancy (SAVI): Gain-of-function STING mutations cause systemic inflammation with neurological involvement
These conditions demonstrate that chronic IFN-I activation alone is sufficient to cause neurodegeneration, even without the protein aggregation pathology seen in AD, PD, and ALS [7].
- Anti-IFNAR1 antibodies: Anifrolumab (approved for lupus) blocks the IFN-I receptor, preventing signaling by all IFN-I subtypes. Preclinical studies show neuroprotection in AD models
- Soluble IFNAR decoys: Engineered receptor ectodomains that sequester IFN-I
- RU.521: A selective cGAS inhibitor that reduces cGAMP production and downstream IFN-I signaling. Demonstrates efficacy in cell-based models of neuroinflammation
- G150: A cGAS inhibitor with improved pharmacokinetic properties
- Challenge: Most cGAS inhibitors have limited [BBB[/entities/blood-brain-barrier penetration, necessitating CNS-targeted delivery strategies
- H-151: A covalent STING inhibitor that palmitoylates STING at Cys91, blocking its activation and translocation. Reduces brain inflammation and microglial synaptic phagocytosis in preclinical models
- C-178: Another covalent STING inhibitor with demonstrated neuroprotective effects
- Berbamine: A natural compound identified as a STING inhibitor with CNS activity
- Novel small molecules: Indole derivatives and STING mutant-specific degraders are in development
- Ruxolitinib, baricitinib, tofacitinib: FDA-approved JAK inhibitors that block IFN-I signaling downstream of IFNAR. Baricitinib has shown preliminary efficacy in Aicardi-Goutières syndrome
- Selective JAK1 inhibitors: May reduce off-target immunosuppression while preserving IFN-I blockade
- Metformin: The widely-used diabetes drug attenuates cGAS-STING-mediated neuroinflammation in preclinical models, potentially through AMPK-dependent mechanisms
- Resveratrol: Modulates IFN-I signaling pathways
- Curcumin: Anti-inflammatory effects partly mediated through IFN-I pathway modulation
- [BBB[/entities/blood-brain-barrier penetration: Many inhibitors fail to achieve sufficient CNS concentrations
- Immune suppression: Systemic IFN-I blockade increases susceptibility to viral infections
- Cell-type specificity: Ideally, therapy should target microglial IFN-I signaling without affecting neuronal IFN-I responses that may be protective
- Timing: IFN-I signaling may be protective early in disease (e.g., clearing protein aggregates) but harmful when chronic
¶ Current Research and Future Directions
- Single-cell profiling of IRM: Defining the full transcriptional and functional heterogeneity of interferon-response microglia across brain regions, disease stages, and genetic backgrounds using [single-cell genomics[/technologies/single-cell-genomics and [spatial transcriptomics[/technologies/spatial-transcriptomics
- Retroelement activation: Understanding how age-related derepression of endogenous retroelements drives IFN-I activation and whether retroelement inhibitors (e.g., reverse transcriptase inhibitors) can slow neurodegeneration
- IFN-I and COVID-19: Post-COVID neurological sequelae may involve sustained IFN-I activation in the brain, with implications for understanding how viral infections accelerate neurodegeneration (Mavrikaki et al., 2024)
- Biomarker development: Plasma and CSF levels of ISGs, cGAMP, and IFN-I subtypes as [biomarkers] for disease staging and therapeutic monitoring
- Combinatorial approaches: Targeting IFN-I signaling alongside [amyloid], tau], or [α-synuclein[/proteins/alpha-synuclein pathology for synergistic therapeutic effects
The study of Interferon Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
0 references |
| Replication |
100% |
| Effect Sizes |
50% |
| Contradicting Evidence |
100% |
| Mechanistic Completeness |
50% |
Overall Confidence: 53%